Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 25 Publications

6 Customer Reviews

  • (F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Paclitaxel purchased from Selleck.

    Effect of tivantinib on the mitotic index was compared with the antimitotic drugs paclitaxel and vinblastine after overnight treatment of the HLE cell line with two different concentrations of each drug.

    Clin Cancer Res, 2017, 23(15):4364-4375. Paclitaxel purchased from Selleck.

  • Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

    Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

  • Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

    Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 M1LsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;pXGZZUUN3ME2wMlAxODJ6NzFOwG0> NELtTGVUSU6JRWK=
LC-2-ad M2m0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwMECwN|E4KM7:TR?= M4PmbnNCVkeHUh?=
RL95-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr6Rmw1UUN3ME2wMlAxODZ4ODFOwG0> NVLVOphpW0GQR1XS
MZ1-PC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzwTWM2OD1yLkCwNFczQSEQvF2= MWTTRW5ITVJ?
TE-8 NVfGbmE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHJRVdMUUN3ME2wMlAxOTF5IN88US=> M{nmSXNCVkeHUh?=
SW954 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTTO49KSzVyPUCuNFAyOTlizszN MXPTRW5ITVJ?
TE-11 MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i3emlEPTB;MD6wNFEzOyEQvF2= MoHRV2FPT0WU
PSN1 NVzOTI53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMECxN{DPxE1? M1\wN3NCVkeHUh?=
MOLT-4 M3f4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LlOmlEPTB;MD6wNFE1QSEQvF2= M{G2S3NCVkeHUh?=
697 M4jGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlu0TWM2OD1yLkCwNVUh|ryP NEnQNYZUSU6JRWK=
ETK-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXSZ5BHUUN3ME2wMlAxOTV{IN88US=> MWDTRW5ITVJ?
TE-10 NX7RWWpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoGzTWM2OD1yLkCwNVU1KM7:TR?= NX;4TGtmW0GQR1XS
HUTU-80 M2W3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMECxOlgh|ryP MV\TRW5ITVJ?
NTERA-S-cl-D1 NH;WZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XvZWlEPTB;MD6wNFIxQSEQvF2= MYjTRW5ITVJ?
MFH-ino MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMECyOlgh|ryP MWDTRW5ITVJ?
IA-LM MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHGTWM2OD1yLkCwNlgh|ryP MULTRW5ITVJ?
MC116 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkezTWM2OD1yLkCwNlg6KM7:TR?= NYO2d3U{W0GQR1XS
RKO MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfR[|BKSzVyPUCuNFAzQThizszN MUnTRW5ITVJ?
MRK-nu-1 M1\nVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMECyPVkh|ryP MlnTV2FPT0WU
VA-ES-BJ NIHvb4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrqTWM2OD1yLkCwN{DPxE1? M1f3S3NCVkeHUh?=
KALS-1 NEX0[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMECzNFgh|ryP MoTyV2FPT0WU
BB30-HNC MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITWXZVKSzVyPUCuNFA{OTRizszN NH7BVGNUSU6JRWK=
ACN MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3tTWM2OD1yLkCwN|E3KM7:TR?= MX;TRW5ITVJ?
TE-9 NVjWNG51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrkXFRKSzVyPUCuNFA{OjZizszN MWHTRW5ITVJ?
SIG-M5 NEn5b5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPFTWM2OD1yLkCwN|I4KM7:TR?= MY\TRW5ITVJ?
no-10 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMECzOlIh|ryP NIPhdoNUSU6JRWK=
EW-1 NFHlSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LlXWlEPTB;MD6wNFM4OSEQvF2= NXHYO4M{W0GQR1XS
SK-LMS-1 M1vMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn4OoVKSzVyPUCuNFA1ODFizszN NWe5OZd5W0GQR1XS
GT3TKB MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwMEC0N|Qh|ryP Mkf0V2FPT0WU
ES4 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7hdZpiUUN3ME2wMlAxPDR7IN88US=> NYTrXXAyW0GQR1XS
IMR-5 NXP6VY9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfJd5lYUUN3ME2wMlAxPDVizszN NVjPOWtOW0GQR1XS
NCI-H1648 NEXZd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLTRpZYUUN3ME2wMlAxPDZ7IN88US=> MnrVV2FPT0WU
MV-4-11 NXXvVmZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMEC0O|Uh|ryP M4XvOXNCVkeHUh?=
SK-UT-1 M1zXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDrcldyUUN3ME2wMlAxPDhizszN MXrTRW5ITVJ?
NB13 NYixZZRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEOwNHBKSzVyPUCuNFA1QTFizszN M2TUXXNCVkeHUh?=
DJM-1 Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrUTWM2OD1yLkCwOVMh|ryP M3mxenNCVkeHUh?=
ES8 M3PoS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlX3TWM2OD1yLkCwOVM5KM7:TR?= M4LEfnNCVkeHUh?=
TE-6 M1fHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3TU3lCUUN3ME2wMlAxPTdizszN MVrTRW5ITVJ?
KS-1 MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D1R2lEPTB;MD6wNFU5OiEQvF2= NVjmWZJpW0GQR1XS
TE-1 MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUC3Z3NMUUN3ME2wMlAxPjB4IN88US=> M1e2fXNCVkeHUh?=
ATN-1 NHfQRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\hUWlEPTB;MD6wNFYxQSEQvF2= M1PoNXNCVkeHUh?=
A4-Fuk NEnmT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMEC2NVEh|ryP MnXHV2FPT0WU
ALL-PO NYfseo9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G2eWlEPTB;MD6wNFY{KM7:TR?= NXfse2d6W0GQR1XS
BE-13 NIrQOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\PTWM2OD1yLkCwOlM3KM7:TR?= NIK2VmlUSU6JRWK=
KM12 NELvb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjXSnJPUUN3ME2wMlAxPjN5IN88US=> M2rBRXNCVkeHUh?=
NOS-1 NEXB[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne1TWM2OD1yLkCwOlUh|ryP MUPTRW5ITVJ?
SW962 NUiySoJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjrTWM2OD1yLkCwOlYzKM7:TR?= MULTRW5ITVJ?
OCUB-M MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwMEC2OlIh|ryP MkDrV2FPT0WU
NCI-H510A MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMEC2OlUh|ryP Mn\xV2FPT0WU
EW-16 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vhU2lEPTB;MD6wNFY6PCEQvF2= Mnq4V2FPT0WU
KGN NFnRW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMEC3NVIh|ryP M1fxdHNCVkeHUh?=
LS-411N MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLy[IpKSzVyPUCuNFA4OTdizszN M2\vTXNCVkeHUh?=
Becker M1ftUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1GxOGlEPTB;MD6wNFczKM7:TR?= NUXBfIFoW0GQR1XS
HC-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnZWnJoUUN3ME2wMlAxPzJzIN88US=> MlXJV2FPT0WU
CESS MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfPTHNjUUN3ME2wMlAxPzN5IN88US=> NIrMNVRUSU6JRWK=
KURAMOCHI MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfFeGVqUUN3ME2wMlAxPzR6IN88US=> NYPqU|FvW0GQR1XS
TGBC24TKB MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMEC3OVIh|ryP NGjOZWNUSU6JRWK=
SW982 NVe1TFRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjLTWM2OD1yLkCwO|Y3KM7:TR?= M4DSWXNCVkeHUh?=
HCE-4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nUZ2lEPTB;MD6wNFc3PyEQvF2= MXHTRW5ITVJ?
LOUCY MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\qTWM2OD1yLkCwO|c2KM7:TR?= NV7teIdsW0GQR1XS
8-MG-BA M13ifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjFTWM2OD1yLkCwO|k3KM7:TR?= M{nFfHNCVkeHUh?=
HT-144 MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWmy[49tUUN3ME2wMlAxQCEQvF2= NYrvc3pDW0GQR1XS
LXF-289 NF3ocY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDSTWM2OD1yLkCwPFE5KM7:TR?= MnjhV2FPT0WU
RS4-11 MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH1TWM2OD1yLkCwPFM3KM7:TR?= Mmr6V2FPT0WU
DEL M4LtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn[zTWM2OD1yLkCwPFQ2KM7:TR?= NFn1bmtUSU6JRWK=
OCI-AML2 NIThOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLPfZlyUUN3ME2wMlAxQDV{IN88US=> NUHQe3ExW0GQR1XS
CCRF-CEM NHvYRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVL3eZpZUUN3ME2wMlAxQDdzIN88US=> NUOwN|dlW0GQR1XS
A388 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXexV3g1UUN3ME2wMlAxQDd2IN88US=> MlXpV2FPT0WU
KNS-42 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDmPXRkUUN3ME2wMlAxQDlzIN88US=> NX;FWIVRW0GQR1XS
OVCAR-4 NUH3SWJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXabXdwUUN3ME2wMlAxQTB2IN88US=> MoXtV2FPT0WU
NCI-H1355 MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jvbGlEPTB;MD6wNFkyPCEQvF2= M4G5T3NCVkeHUh?=
BL-70 NXHyW5puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMEC5N{DPxE1? M2Dq[nNCVkeHUh?=
BL-41 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLqcG5KSzVyPUCuNFA6OzRizszN MUXTRW5ITVJ?
A101D MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMEC5OkDPxE1? NW\Te|M6W0GQR1XS
HL-60 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPoXXh6UUN3ME2wMlAxQTZ4IN88US=> NEi1[|lUSU6JRWK=
COR-L279 NHnrcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMEC5PVkh|ryP NWD2U|UyW0GQR1XS
NCI-SNU-16 NFuw[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jWcmlEPTB;MD6wNVAxQCEQvF2= M{nxdHNCVkeHUh?=
Calu-6 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfoRW17UUN3ME2wMlAyODF{IN88US=> MWTTRW5ITVJ?
SR MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu0U5lUUUN3ME2wMlAyODJ4IN88US=> NF\TTolUSU6JRWK=
QIMR-WIL MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDiTWM2OD1yLkCxNFM{KM7:TR?= Mn73V2FPT0WU
LB647-SCLC NVS0NJFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7MOI1DUUN3ME2wMlAyODVzIN88US=> NVrQd3RoW0GQR1XS
RPMI-8226 M{PITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXV[YZKSzVyPUCuNFEyODJizszN MmG1V2FPT0WU
SK-PN-DW MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwMEGxNVIh|ryP MVnTRW5ITVJ?
SF268 M{TZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMEGxOVEh|ryP NXXT[Jl{W0GQR1XS
HD-MY-Z MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH1PXRzUUN3ME2wMlAyOTZ|IN88US=> NWfPRlhXW0GQR1XS
DOHH-2 NXf4RVRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLl[4FvUUN3ME2wMlAyOjB|IN88US=> NFLteJdUSU6JRWK=
SCC-3 NEe2VHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLlTFRbUUN3ME2wMlAyOjB2IN88US=> MlX2V2FPT0WU
ST486 Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPHc4JKSzVyPUCuNFEzODRizszN MmPLV2FPT0WU
NALM-6 NIiwW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnTbpJKSzVyPUCuNFEzOTRizszN NXvuO3g5W0GQR1XS
NCI-H1436 NVvXfll6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrOSGZOUUN3ME2wMlAyOjNzIN88US=> M2HHPXNCVkeHUh?=
KE-37 M37Sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XWRmlEPTB;MD6wNVI{PCEQvF2= NU\Qc4RIW0GQR1XS
RPMI-8402 NGrMXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33y[2lEPTB;MD6wNVI2PiEQvF2= NWnrbGdHW0GQR1XS
RXF393 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHZTWM2OD1yLkCxNlU4KM7:TR?= NIXTeXNUSU6JRWK=
KARPAS-45 M3rkPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMEGyO{DPxE1? NF2zc5BUSU6JRWK=
HOP-62 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEO4[pFKSzVyPUCuNFEzPzZizszN NIHvOoRUSU6JRWK=
ES1 NWX4Sox{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HPUGlEPTB;MD6wNVI5QCEQvF2= M3jJXHNCVkeHUh?=
L-363 MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LkV2lEPTB;MD6wNVM2OSEQvF2= MmXvV2FPT0WU
GI-1 NXLyRYpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;KcVVKSzVyPUCuNFE{PzNizszN MWTTRW5ITVJ?
CTV-1 MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrHRmdKSzVyPUCuNFE1PzhizszN MmXTV2FPT0WU
TE-5 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jyd2lEPTB;MD6wNVQ6PiEQvF2= Mle0V2FPT0WU
SNU-C2B MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq3cHQ4UUN3ME2wMlAyPDl4IN88US=> M4TWTHNCVkeHUh?=
K-562 NIrlcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX6eJRKSzVyPUCuNFE2OTZizszN NXLnbYU{W0GQR1XS
SNB75 M4PLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzFT2duUUN3ME2wMlAyPTRizszN M1;LS3NCVkeHUh?=
MOLT-13 M3HEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i1OWlEPTB;MD6wNVY{PyEQvF2= MnXHV2FPT0WU
LS-123 NVfSTFhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[wNmRDUUN3ME2wMlAyPjZ2IN88US=> MYLTRW5ITVJ?
NCI-SNU-5 NYDuOVZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m1dGlEPTB;MD6wNVcxOSEQvF2= M4fqdHNCVkeHUh?=
Daudi MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\nPGlEPTB;MD6wNVcxQCEQvF2= MV3TRW5ITVJ?
A253 MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TSfmlEPTB;MD6wNVc{QCEQvF2= MXTTRW5ITVJ?
TGBC1TKB NITIdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWGwU2RHUUN3ME2wMlAyPzV{IN88US=> NXSxV2RsW0GQR1XS
SJSA-1 NIXjNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\CZnlKSzVyPUCuNFE4PjdizszN NFvHfmNUSU6JRWK=
NCCIT NUHG[JdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1e0bGlEPTB;MD6wNVc3QSEQvF2= MV3TRW5ITVJ?
NCI-H69 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mon4TWM2OD1yLkCxO|c5KM7:TR?= NFjwdYdUSU6JRWK=
SH-4 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHq2TZFKSzVyPUCuNFE5QTVizszN NIfteFRUSU6JRWK=
HCC1187 MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwMEG5NlQh|ryP MmfLV2FPT0WU
HCC1599 NI\DNWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMEKwNkDPxE1? M{\OTHNCVkeHUh?=
ONS-76 MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwMEKwN|Yh|ryP MkLrV2FPT0WU
KU812 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWi1RmZ{UUN3ME2wMlAzODN7IN88US=> NXHGZ2ZtW0GQR1XS
ML-2 Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\WUYl[UUN3ME2wMlAzODR5IN88US=> NG\Qd2dUSU6JRWK=
HCE-T M3;NbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMEKwPVIh|ryP NWTCTVZrW0GQR1XS
NCI-H446 NGDxZ|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF74WpRKSzVyPUCuNFIyOTJizszN NGjmR29USU6JRWK=
RPMI-6666 NXHQN4xrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[0RohqUUN3ME2wMlAzOTR7IN88US=> MVzTRW5ITVJ?
MOLT-16 NH\ZbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzPV2lKSzVyPUCuNFIyPTNizszN NIK3Zm1USU6JRWK=
JiyoyeP-2003 M2XXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWr6XVhnUUN3ME2wMlAzOTd4IN88US=> NYixSVByW0GQR1XS
MHH-PREB-1 NFniPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMEKxPVEh|ryP NWf0bopGW0GQR1XS
MC-CAR NFjufZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELP[IdKSzVyPUCuNFI{OjZizszN NX7SWnl3W0GQR1XS
BC-3 NUX2UZVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUH3SoJpUUN3ME2wMlAzOzR2IN88US=> M4\QPXNCVkeHUh?=
KINGS-1 M17lPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1y3R2lEPTB;MD6wNlM2PSEQvF2= MXnTRW5ITVJ?
PF-382 NFSyPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMEKzO|gh|ryP MXXTRW5ITVJ?
J-RT3-T3-5 M3\pTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu2XZNZUUN3ME2wMlAzOzh|IN88US=> NGq0NodUSU6JRWK=
SF539 NXHMWpNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f6PGlEPTB;MD6wNlQxOSEQvF2= M4DHOXNCVkeHUh?=
LB831-BLC M3zYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn65TWM2OD1yLkCyOFg2KM7:TR?= NGD0UFNUSU6JRWK=
DMS-114 NFTadXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;i[GpjUUN3ME2wMlAzPTB{IN88US=> MlnDV2FPT0WU
LB1047-RCC NUDqR5NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvib|BKSzVyPUCuNFI2OSEQvF2= NUnpO2Z3W0GQR1XS
LB771-HNC MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC4TWM2OD1yLkCyOVM1KM7:TR?= NGDU[JZUSU6JRWK=
BB65-RCC NVPaR4VZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrQUZlKSzVyPUCuNFI2OzRizszN MUjTRW5ITVJ?
BV-173 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{OyeWlEPTB;MD6wNlU2PCEQvF2= NW[wSZY6W0GQR1XS
ARH-77 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPQfpBOUUN3ME2wMlAzPjBzIN88US=> NHjwblNUSU6JRWK=
IST-MEL1 NEj6SIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMEK2NlMh|ryP MYTTRW5ITVJ?
NB1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfMTWM2OD1yLkCyOlg4KM7:TR?= NGXwNItUSU6JRWK=
EoL-1-cell MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMEK2PFgh|ryP MoOxV2FPT0WU
KY821 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXZfWFKSzVyPUCuNFI3QTdizszN M2TiV3NCVkeHUh?=
CMK M17sPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\Fc25JUUN3ME2wMlAzPzN2IN88US=> NXHkd4tDW0GQR1XS
NCI-H2126 NYm1[VlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMEK3Olgh|ryP MoPNV2FPT0WU
NCI-H526 NVPEeXlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnrTWM2OD1yLkCyPFkyKM7:TR?= MnTiV2FPT0WU
COLO-684 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjqW|FKSzVyPUCuNFI6ODhizszN MYfTRW5ITVJ?
NCI-H747 M2C1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMEK5N|Mh|ryP MVjTRW5ITVJ?
JAR Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X0OmlEPTB;MD6wNlk1PiEQvF2= M1nNWXNCVkeHUh?=
MEG-01 Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDQOWhOUUN3ME2wMlAzQTd6IN88US=> NXjFNW1vW0GQR1XS
MONO-MAC-6 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlf3TWM2OD1yLkCzNFI{KM7:TR?= M1fnPXNCVkeHUh?=
IST-SL1 NIPVTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjBOWM1UUN3ME2wMlA{ODR{IN88US=> MmixV2FPT0WU
CPC-N M3v0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHlXIRKSzVyPUCuNFMxPzlizszN M{DaTnNCVkeHUh?=
NCI-H1963 M4rIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGG1OG1KSzVyPUCuNFMyOzFizszN NWHsdFFJW0GQR1XS
K052 NYjiRpJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF31PYJKSzVyPUCuNFMzPDdizszN MVrTRW5ITVJ?
KM-H2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXabodKSzVyPUCuNFM{ODdizszN M1zzcnNCVkeHUh?=
TE-12 MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jUV2lEPTB;MD6wN|MxQSEQvF2= M{Dn[HNCVkeHUh?=
TK10 M1SyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXFTWM2OD1yLkCzN|U3KM7:TR?= MknFV2FPT0WU
NMC-G1 M3rNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnnTWM2OD1yLkCzOFUzKM7:TR?= NIqwR3hUSU6JRWK=
no-11 MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX6TWM2OD1yLkCzOFc5KM7:TR?= MmnVV2FPT0WU
NCI-H524 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrxRmtKSzVyPUCuNFM2OjlizszN NV71ZnFNW0GQR1XS
MHH-CALL-2 NWfYNYZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfkTWM2OD1yLkCzOVYzKM7:TR?= MojrV2FPT0WU
GB-1 NYe0[oFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{O0NmlEPTB;MD6wN|Yh|ryP NWfBbodJW0GQR1XS
OPM-2 NEj0eG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPxcmJlUUN3ME2wMlA{Pjd|IN88US=> MmDyV2FPT0WU
RH-1 NVT4PXNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHpTWM2OD1yLkCzPFE6KM7:TR?= MUHTRW5ITVJ?
NCI-H64 MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HETGlEPTB;MD6wN|g2PyEQvF2= NYPXc4tkW0GQR1XS
EVSA-T Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXmb41jUUN3ME2wMlA{QTJ|IN88US=> MV7TRW5ITVJ?
KARPAS-299 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXTTWM2OD1yLkCzPVgh|ryP M17ZNXNCVkeHUh?=
MZ7-mel M1XqZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnnOVJKSzVyPUCuNFQxPCEQvF2= M{fUU3NCVkeHUh?=
LB373-MEL-D NXryNmpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMESxNFUh|ryP NELJOXpUSU6JRWK=
HEL NWfUWWl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\v[YNXUUN3ME2wMlA1OTRizszN NXvTXJI3W0GQR1XS
SW872 MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvXTWM2OD1yLkC0NlEh|ryP NX;XTocyW0GQR1XS
DU-4475 MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPsd45KSzVyPUCuNFQzPDRizszN NWXlSnltW0GQR1XS
IST-SL2 NU\xcYZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnHVnNKSzVyPUCuNFQzPzVizszN M323XXNCVkeHUh?=
NCI-H82 NEj6WXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LOSWlEPTB;MD6wOFMxPyEQvF2= MmC0V2FPT0WU
LC4-1 NFPQOllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\CU2lEPTB;MD6wOFM2OSEQvF2= MYDTRW5ITVJ?
HDLM-2 NICxVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMESzPVIh|ryP MWjTRW5ITVJ?
MMAC-SF NF3XOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LEWGlEPTB;MD6wOFU{PCEQvF2= MXzTRW5ITVJ?
L-540 MmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPuOolXUUN3ME2wMlA1PjN7IN88US=> NH;McXJUSU6JRWK=
MZ2-MEL MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPrTWM2OD1yLkC0O|QzKM7:TR?= M1LlRnNCVkeHUh?=
LU-134-A NYrtcIdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXnTHdKSzVyPUCuNFQ4PzNizszN MW\TRW5ITVJ?
UACC-257 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1j2WGlEPTB;MD6wOFg1QSEQvF2= NU\sUFFGW0GQR1XS
NCI-H1581 MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fQXGlEPTB;MD6wOFk2OyEQvF2= NHjGSZhUSU6JRWK=
NB17 NYj0SGE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\tZ3RKSzVyPUCuNFQ6PzlizszN MXLTRW5ITVJ?
SBC-1 M{LpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\SfnBKSzVyPUCuNFUxPDJizszN MkLiV2FPT0WU
TALL-1 NWH0UHhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUGxPWpWUUN3ME2wMlA2ODR3IN88US=> MWLTRW5ITVJ?
NCI-H1304 M4HqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nJWWlEPTB;MD6wOVIxQCEQvF2= M2S0VnNCVkeHUh?=
NEC8 MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPQT4JKUUN3ME2wMlA2Ojh4IN88US=> M1jGZnNCVkeHUh?=
CAL-148 NF;vUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFmzfVFKSzVyPUCuNFU1OzlizszN NVfqNo9xW0GQR1XS
CGTH-W-1 NGTQcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMEW0OFkh|ryP MYjTRW5ITVJ?
NCI-H889 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlSyTWM2OD1yLkC1OVkzKM7:TR?= MYXTRW5ITVJ?
GR-ST NUnC[FJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fZbmlEPTB;MD6wOVYzOSEQvF2= MXvTRW5ITVJ?
KARPAS-422 NXG3SndoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMEW2OUDPxE1? MYjTRW5ITVJ?
RPMI-8866 NXPwPXB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2T4WWlEPTB;MD6wOVcyOiEQvF2= NGSyPJNUSU6JRWK=
SCLC-21H MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPrTWM2OD1yLkC1PFg1KM7:TR?= M4OwenNCVkeHUh?=
COR-L88 M{jYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoOzTWM2OD1yLkC1PVI4KM7:TR?= M2DqW3NCVkeHUh?=
LU-139 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D5bWlEPTB;MD6wOVk5PiEQvF2= Ml\6V2FPT0WU
SF126 Mn7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr0dYxKSzVyPUCuNFYyOzNizszN NGLDPHJUSU6JRWK=
NCI-H1882 MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;MTWM2OD1yLkC2OFI1KM7:TR?= M{HYVHNCVkeHUh?=
EW-24 NX7xWXFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3pbVMxUUN3ME2wMlA3PDh|IN88US=> MnPMV2FPT0WU
CP67-MEL M2XmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS0TWM2OD1yLkC2PFEh|ryP MnPDV2FPT0WU
DG-75 NE\6VJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D5XGlEPTB;MD6wOlg6QSEQvF2= NF62dWJUSU6JRWK=
LOXIMVI MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPOTWM2OD1yLkC3NFI5KM7:TR?= NHvVdoJUSU6JRWK=
HH MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjWVIRKSzVyPUCuNFcyPTdizszN MX;TRW5ITVJ?
K5 M{PRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMEeyNlYh|ryP MmDxV2FPT0WU
EC-GI-10 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMEeyOVch|ryP MX3TRW5ITVJ?
SK-N-DZ M1r6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljjTWM2OD1yLkC3N|A4KM7:TR?= MlL4V2FPT0WU
A3-KAW MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwMEezOVEh|ryP M3PD[nNCVkeHUh?=
MLMA MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwMEe0OlUh|ryP NWLqU|hPW0GQR1XS
LB996-RCC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXhRYpiUUN3ME2wMlA4PzB5IN88US=> NFHqdG9USU6JRWK=
OS-RC-2 NIjnc3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXLb5pKSzVyPUCuNFc4PDhizszN M1HQfHNCVkeHUh?=
CTB-1 M1[wS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnJdlYyUUN3ME2wMlA4QDFizszN NGHwZolUSU6JRWK=
IST-MES1 M{\SPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnM[3JYUUN3ME2wMlA4QTF{IN88US=> MoHUV2FPT0WU
LS-1034 M1iwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn0bJNKSzVyPUCuNFgxOzVizszN NX3HWGUzW0GQR1XS
HT MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHXTWM2OD1yLkC4NFg3KM7:TR?= MmfRV2FPT0WU
NCI-H2141 MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7BSHBpUUN3ME2wMlA5OSEQvF2= M1P0NHNCVkeHUh?=
LB2518-MEL M{f3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{C1V2lEPTB;MD6wPFE1OSEQvF2= NWnnclR1W0GQR1XS
GI-ME-N M3XMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzyTWM2OD1yLkC4OFUzKM7:TR?= MVvTRW5ITVJ?
TGW MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[5TWM2OD1yLkC4OlA4KM7:TR?= NYrNUZU2W0GQR1XS
SK-NEP-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMEi2OFEh|ryP M2ThbHNCVkeHUh?=
NOMO-1 MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnXb4VKSzVyPUCuNFkzPzVizszN MVXTRW5ITVJ?
ES6 Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DrUWlEPTB;MD6wPVU5QSEQvF2= NXPjdGhjW0GQR1XS
NCI-H209 M1v6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HSZWlEPTB;MD6wPVc5PiEQvF2= M2naZnNCVkeHUh?=
GAK MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPQd2h5UUN3ME2wMlExOTZizszN NVi3Zo5[W0GQR1XS
BC-1 M1Ttc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT0TWM2OD1yLkGwN|YyKM7:TR?= M1\vU3NCVkeHUh?=
KLE NHnTRVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j0UGlEPTB;MD6xNFQ1OyEQvF2= NHPhSnNUSU6JRWK=
EW-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHSOIRKSzVyPUCuNVA6QCEQvF2= MY\TRW5ITVJ?
NKM-1 NGXae2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWW5bHZRUUN3ME2wMlEyOSEQvF2= NWGwSZl6W0GQR1XS
D-336MG Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwMUGyOFQh|ryP MmL1V2FPT0WU
NB69 NYjDWJFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjRXGRoUUN3ME2wMlEyOzBzIN88US=> NGG3WHBUSU6JRWK=
D-263MG NWS3XIhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnUOFkyUUN3ME2wMlEyPzF{IN88US=> NXjFXo5DW0GQR1XS
KP-N-YS NWPaTmJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPHb|BWUUN3ME2wMlEzOjlzIN88US=> NFnZR|FUSU6JRWK=
NCI-H1155 NYrUXZM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;WTWM2OD1yLkGyOVU5KM7:TR?= MXnTRW5ITVJ?
BOKU Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP1eXFxUUN3ME2wMlEzPTd7IN88US=> M17ubHNCVkeHUh?=
LAMA-84 M3PucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fsUGlEPTB;MD6xNlk6KM7:TR?= M2H5fHNCVkeHUh?=
Raji MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwMUOxNVch|ryP MXXTRW5ITVJ?
LU-65 Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnqxTWM2OD1yLkGzN|A4KM7:TR?= NGT4bYVUSU6JRWK=
NCI-H187 M4O4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;TTWM2OD1yLkGzPVI1KM7:TR?= Mm\RV2FPT0WU
GCIY NXH4PXRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\DRld6UUN3ME2wMlE1QTBzIN88US=> NV3Hd3J6W0GQR1XS
NCI-H2107 Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\lW3RvUUN3ME2wMlE2ODhizszN MXjTRW5ITVJ?
NCI-H1522 NYf0UFRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfGU457UUN3ME2wMlE2OjZ4IN88US=> NYfiXFQ6W0GQR1XS
NB6 MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\tNJB7UUN3ME2wMlE2PjJ|IN88US=> NFi2VWZUSU6JRWK=
EM-2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTZflBKSzVyPUCuNVU4ODZizszN NGnLeHVUSU6JRWK=
HCC2218 MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjBcodqUUN3ME2wMlE2QThizszN M1nEc3NCVkeHUh?=
NCI-H748 NHv3[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXsVFk6UUN3ME2wMlE3Ozd4IN88US=> MUjTRW5ITVJ?
MS-1 NXiyfHR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMU[1N|ch|ryP NYDufm01W0GQR1XS
NB5 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\aPGlEPTB;MD6xOlU6PyEQvF2= MWXTRW5ITVJ?
OMC-1 M3rve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn5XHVKSzVyPUCuNVY3QDhizszN M33UfnNCVkeHUh?=
NCI-H345 M1;EfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\2XlJKSzVyPUCuNVY6OjhizszN MWPTRW5ITVJ?
L-428 MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;6[HNKSzVyPUCuNVY6PDVizszN MnX3V2FPT0WU
SCH MkjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr6VJhKSzVyPUCuNVg3QDVizszN NWPXVHM6W0GQR1XS
NCI-H1417 NWqwbWV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LrNWlEPTB;MD6xPVIzPyEQvF2= M4PSNHNCVkeHUh?=
COLO-320-HSR MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fsSGlEPTB;MD6xPVU{OiEQvF2= MkLqV2FPT0WU
BT-474 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMkC4PVIh|ryP NWjkWGpSW0GQR1XS
GDM-1 M3Kzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HyZ2lEPTB;MD6yNVk4OSEQvF2= NULrWmFkW0GQR1XS
NCI-H2196 NXH5c2pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHCTWM2OD1yLkKyNlM2KM7:TR?= MWfTRW5ITVJ?
KP-N-RT-BM-1 MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XZN2lEPTB;MD6yNlM1QSEQvF2= MoOyV2FPT0WU
KNS-81-FD Mn:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon1TWM2OD1yLkKyPVU5KM7:TR?= M3z0fnNCVkeHUh?=
COLO-668 Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XJXWlEPTB;MD6yN|Y4PSEQvF2= MlXtV2FPT0WU
C2BBe1 Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzUTWM2OD1yLkK2O|Q4KM7:TR?= MVLTRW5ITVJ?
Ramos-2G6-4C10 Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHrTWM2OD1yLkK2PVU1KM7:TR?= NGHibmJUSU6JRWK=
CAS-1 MlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkWwTWM2OD1yLkK3NFk3KM7:TR?= NVzWeYVtW0GQR1XS
GOTO M3\uSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\3TGlEPTB;MD6yO|g6PCEQvF2= MmL6V2FPT0WU
LP-1 NXLIPFFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfMTWM2OD1yLkK4NFU4KM7:TR?= MoftV2FPT0WU
NCI-SNU-1 NFr4fHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj5XHhKSzVyPUCuNlk1OjJizszN M{T0OnNCVkeHUh?=
EB-3 Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMkm5O|kh|ryP M{TsRnNCVkeHUh?=
MHH-NB-11 M1\m[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHaU|JwUUN3ME2wMlMxPDB{IN88US=> NX[0eXloW0GQR1XS
SK-N-FI MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm4TWM2OD1yLkOxOlkzKM7:TR?= NGHzNlFUSU6JRWK=
HCC2157 M{Pnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwM{O5NVMh|ryP MoHzV2FPT0WU
SIMA MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfuRZBtUUN3ME2wMlM1PThzIN88US=> M1\FO3NCVkeHUh?=
MDA-MB-134-VI Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWT4ZZkyUUN3ME2wMlM3QTJ6IN88US=> M3;ib3NCVkeHUh?=
NCI-H1694 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjOZphGUUN3ME2wMlM4KM7:TR?= Mn\MV2FPT0WU
EHEB NUjwcFRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq3dpRoUUN3ME2wMlM6ODh3IN88US=> M17lUHNCVkeHUh?=
U-266 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7lVXNkUUN3ME2wMlM6QDR4IN88US=> NGLHNGVUSU6JRWK=
LC-1F MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD0W2FKSzVyPUCuOFM4PjVizszN NX7We3ZwW0GQR1XS
SHP-77 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWCwRllrUUN3ME2wMlQ4QDV3IN88US=> NX7FOZJZW0GQR1XS
LS-513 MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jBVGlEPTB;MD60PVMxPyEQvF2= NVjEVZlnW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ERK / ERK; 

PubMed: 20068074     


Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells.

MARCKS (pSer159/163); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

Src (pTyr416); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; 

PubMed: 29849942     


OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot.

Id1; 

PubMed: 25344919     


(A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner.

MARCKS; 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

20068074 26015406 29849942 25344919
Growth inhibition assay
Cell viability; 

PubMed: 28823711     


Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.

28823711
Immunofluorescence
α-tubulin; 

PubMed: 22904633     


Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel.

Rab11a/BV9; 

PubMed: 29290815     


Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).

22904633 29290815
In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • Concentrations: 0.1-100 pM
  • Incubation Time: 72 hours
  • Method:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (Only for Reference)
Animal Research:

[4]

+ Expand
  • Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • Dosages: 20 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+5% Tween 80+ddH2O
For best results, use promptly after mixing.
2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 853.91
Formula

C47H51NO14

CAS No. 33069-62-4
Storage powder
in solvent
Synonyms NSC 125973

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic December 1 2019 Phase 1|Phase 2
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic December 1 2019 Phase 1|Phase 2
NCT03818997 Not yet recruiting Esophageal Cancer|Biliary Tract Cancer|GastroEsophageal Cancer|Hepatobiliary Neoplasm European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche|Leap Therapeutics Inc. August 2019 Phase 2
NCT03818997 Not yet recruiting Esophageal Cancer|Biliary Tract Cancer|GastroEsophageal Cancer|Hepatobiliary Neoplasm European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche|Leap Therapeutics Inc. August 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • Answer:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • Answer:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Tags: buy Paclitaxel | Paclitaxel supplier | purchase Paclitaxel | Paclitaxel cost | Paclitaxel manufacturer | order Paclitaxel | Paclitaxel distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID